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Enzootic strains of Venezuelan equine encephalitis
virus (VEEV) circulate in forested habitats of Mexico,
Central, and South America, and spiny rats (Proechimys
spp.) are believed to be the principal reservoir hosts in sev-
eral foci. To better understand the host-pathogen interac-
tions and resistance to disease characteristic of many
reservoir hosts, we performed experimental infections of F1
progeny from Proechimys chrysaeolus collected at a
Colombian enzootic VEEV focus using sympatric and
allopatric virus strains. All animals became viremic with a
mean peak titer of 3.3 log10 PFU/mL, and all seroconverted
with antibody titers from 1:20 to 1:640, which persisted up
to 15 months. No signs of disease were observed, includ-
ing after intracerebral injections. The lack of detectable dis-
ease and limited histopathologic lesions in these animals
contrast dramatically with the severe disease and
histopathologic findings observed in other laboratory
rodents and humans, and support their role as reservoir
hosts with a long-term coevolutionary relationship to VEEV.
V
enezuelan equine encephalitis (VEE) is an emerging
disease that affected humans and equines in many
parts of the Americas throughout the 20th century (1–6).
The etiologic agent is VEE virus (VEEV), a positive-sense
RNA virus in the family Togaviridae and genus
Alphavirus. The first strain of VEEV was isolated and
characterized serologically in 1938 (7,8). Numerous
VEEV strains and closely related alphaviruses have since
been classified into 2 epidemiologic groups: enzootic and
epizootic strains. Enzootic strains (subtypes I, varieties D-
F, and subtypes II-VI) are regularly isolated in lowland
tropical forests in Florida, Mexico, and Central and South
America, where they circulate between Culex
(Melanoconion) spp. mosquito vectors and small rodents;
these strains are generally avirulent for and incapable of
amplification in equines (4,9,10). In contrast, epizootic
VEEV strains (subtype I, varieties A-B and C), which are
responsible for all major outbreaks in humans and equines,
use several mosquito vectors and equines, which are
exploited as highly efficient amplification hosts (11,12).
Epizootic viruses cause debilitating disease with high
fatality rates in equines. Humans are tangential, spillover
hosts in both epidemic and enzootic VEEV cycles and are
affected by most strains. A severe febrile illness that can
occasionally be life-threatening develops; although human
death occurs in <1% of infections with enzootic and epi-
zootic VEEV strains, neurologic sequelae occur in sur-
vivors, particularly children (13).
Reservoir hosts play an important role in the replica-
tion, maintenance, and dissemination of arthropodborne
viruses (arboviruses). These hosts generally show little or
no disease after infection, presumably reflecting long-term
selection for host resistance and possibly for virus attenu-
ation (14,15). Changes in the habitats and ecology of reser-
voirs due to anthropogenic or natural causes can affect
pathogen transmission to humans and domestic animals
(16–18). Therefore, understanding how pathogens affect
reservoir fitness, as well as how the reservoir affects
pathogen replication and transmission, could facilitate pre-
diction of emergence, reemergence, or extinction of sylvat-
ic pathogens in response to environmental changes
including deforestation. A better understanding of
pathogen-reservoir interactions, particularly mechanisms
of disease resistance, may also enhance the development
of treatments for humans and domestic animals.
Field studies in Panama have identified antibodies to
VEEV in many different species of mammals, including
Proechimys spp. (spiny rats), Sigmodon spp. (cotton rats),
Marmosa spp. (mouse opossums), Didelphis marsupialis
(opossums), and Chiroptera (bats) (1,19–22). However,
Proechimys spp. (family Echimyidae) and Sigmodon spp.
(family  Muridae) are thought to be principal reservoir
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nature, have high rates of immunity, and viremia develops
in them after laboratory infection (20,23,24). These 2
rodents have different, but overlapping, geographic distri-
butions; Proechimys spp. are found in Panama, northern
Peru, Bolivia, Paraguay, and southern Brazil, whereas
Sigmodon spp. are found from southern North America to
northern parts of Venezuela and Peru. Proechimys spp. can
be abundant in their forested habitats (25). They have a
gestation period of 60 to 70 days and give birth to 2 to 3
pups per litter. Their natural life expectancy is ≈20 months
and can exceed 2 years. 
The relationships between rodent reservoir hosts and
VEEV have received little study. Spiny rats (Proechimys
semispinosus) captured in a VEEV-enzootic region of
Panama exhibited ≈67% seropositivity (1). When spiny
rats were infected with a local subtype ID VEEV strain,
high-titer viremia developed, suggesting their role as reser-
voir hosts. Antibody was detectable by day 3 and persisted
for up to 9 months (20). The role of spiny rats as VEEV
reservoirs was reinforced by a study in Colombia and
Venezuela in which a correlation was established between
the abundance of these rodents and levels of enzootic cir-
culation (10). Experimental infections of Sigmodon spp.
also support their role as reservoir hosts, and horizontal
transmission has been demonstrated among cage mates
(20,23,24). However, none of these studies of spiny and
cotton rats has investigated the clinical or histopathologic
manifestations of VEEV infection in these reservoir
rodents. 
We examined interactions between VEEV isolates from
an enzootic focus in the Middle Magdalena Valley of
Colombia (10) and sympatric P. chrysaeolus. The lack of
detectable disease and limited histopathologic effects on
these animals contrast dramatically with the severe disease
and histopathologic changes observed in other laboratory
rodents and humans, and support their role as reservoir
hosts with a long-term coevolutionary relationship to
VEEV.
Materials and Methods
Animals
P. chrysaeolus (spiny rats) were obtained from a colony
established at the Instituto Nacional de Salud, Bogotá,
Colombia, from adults captured in the Monte San Miguel
Forest in the Middle Magdalena Valley (10). The rats were
identified using mitochondrial DNAsequence analysis and
karotyping (J. Patton, University of California, Berkeley,
CA, pers. comm.) (26). Male and female F1 offspring 3–36
months of age were used for experimental infections. The
animals were housed in conventional rat cages and fed lab-
oratory rat chow. All animals were tested for neutralizing
antibodies against VEEV, and seronegative animals were
infected in accordance with animal care and use guidelines
of the Instituto Nacional de Salud. Organs were fixed for
48 h in 4% buffered formalin, embedded in paraffin, sec-
tioned (5 µm), and stained with hematoxylin and eosin.
Viruses
Enzootic subtype ID VEEV strain Co97-0054 was iso-
lated in 1997 from a sentinel hamster in the same
Colombian forest where the spiny rats originated (10).
This virus was passaged once in baby hamster kidney 21
cells before animal inoculations. Enzootic strain 66637
was isolated in 1981 from a sentinel hamster in Zulia State,
Venezuela (27), and had 1 passage in suckling mouse cells
and 1 passage in African green monkey kidney (Vero)
cells.
Infections
Before infection, the animals were weighed and their
body temperature was measured rectally. Animals were
injected by the subcutaneous (SC) route into the left foot-
pad with 3 log10 PFU/mL of virus in a 50-µL volume, a
dose consistent with alphavirus saliva titers in mosquitoes
(28). 
Virologic and Histologic Tests
Infected animals were bled and weighed daily follow-
ing ether anesthesia, and their body temperatures were
recorded on days 1 to 4 and day 7. Blood samples were
also collected from some animals at 1 month, 15 months,
or both, postinfection. Blood was diluted 1:10 in Eagle
minimal essential medium supplemented with 20% fetal
bovine serum, gentamicin, and L-glutamine, and stored at
–80°C. Viremia and levels of neutralizing antibodies were
determined by plaque assay and 80% plaque reduction
neutralization tests using Vero cells. For histologic analy-
ses, 4 animals from days 1 to 4 postinfection and 2 from
day 7 were killed and organs were collected. Samples con-
taining virus and viral RNA from the heart, brain, liver,
and kidneys of 2 animals killed on each of days 1–4 were
homogenized and centrifuged for 10 min at 5,760 × g, and
the supernatant fluids were stored at –80°C before virus
titration or RNA extraction. 
Neurovirulence Studies
Four animals were injected by the intracranial (IC)
route with 3 log10PFU of virus strain Co97-0054 following
anesthesia with ketamine/xylazine (50/5 mg/kg). Animals
were monitored for signs of illness, including loss of activ-
ity, ruffled coat, dehydration, anorexia, and neurologic dis-
order (erratic movements of legs or head), and bled daily
for 4 days for viremia titration and on day 15 to determine
seroconversion. 
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RNA was extracted from triturated tissues with Trizol
LS (GIBCO, Grand Island, NY, USA) following the man-
ufacturer’s protocol. DNA primers (5′-CGACA-
GAAAACCAGCAGAGACCTTG-3′, reverse primer:
5′-TCTAACATAGCCATCGTGCCCGTC-3′) were
designed to amplify the VEEV genome at positions
8431–8677. cDNA was obtained by combining 1 µg of
RNA in 10 mmol/L of dithiothreitol, 20 nmol/L of
deoxynucleotide triphosphates (dNTPs), 4 µL of 5× first-
strand buffer, 40 U of RNAse inhibitor, 100 ng/µLo f
minus sense primer, and water to give a final volume of 20
µL, and incubated for 2 min at 40°C. Two hundred units of
reverse transcriptase (Superscript, GIBCO) were added,
and the sample was incubated overnight at 42°C. A poly-
merase chain reaction (PCR) included 1 µg of cDNA, 300
ng of each primer, 10 µL of 10× Taq buffer (GIBCO), 1.25
mmol/L of Mg2+, 20 nmol/L of dNTPs, 5 U of Taq enzyme
(GIBCO), and water to a final volume of 100 µL. Thirty
cycles were performed, including denaturation at 95°C for
1 min, annealing at 59°C for 30 s, and extension at 72°C
for 2 min, followed by a 10-min extension time at 72°C.
PCR products were analyzed by electrophoresis on a 1%
agarose gel, and DNA products were purified by using a
QIAquick PCR purification kit (Qiagen, Valencia, CA,
USA). PCR products were sequenced by using the sense
primer and the ABI PRISM Big Dye Terminator v3.0 kit
(Applied Biosystems, Foster City, CA, USA) following the
manufacturer’s recommendations.
Statistical Analyses
Linear regression was used to analyze the influence of
age on peak level of viremia. One-way analysis of variance
was used to analyze tissue and viremia data. Body temper-
ature differences were analyzed using the SAS/STAT pro-
cedure MIXED for repeated measures (SAS/STAT Users
Guide, Volumes 1, 2, and 3, Version 8, SAS Institute, Cary,
NC, USA).
Results
Clinical Manifestations 
Twenty rats were infected with the enzootic ID strain
Co97-0059, and 2 rats were infected with the enzootic
strain 66637. All animals were monitored twice a day for
clinical signs of VEEV infection, and none showed any
signs of disease or discomfort, abnormal activity, disturbed
social behavior, or loss of appetite, as compared with the
uninfected control. No significant changes in body temper-
ature were observed (p>0.25; data not shown). The 3 ani-
mals injected IC with strain Co97-0054 survived and
showed no signs of illness. Of all animals infected either
SC or IC (n = 27), only 1 showed clinical signs (hyperther-
mia) and died on day 3 postinfection. Whether death was
due to VEEV or another cause is not clear. Histopathologic
results from this animal are presented below. Viral titers in
this animal were similar to those of others infected with the
same virus.
Viral Replication and Tissue Tropism
In animals infected SC with the sympatric enzootic
strain Co97-0054 peak viremia levels of up to 3.3
log10PFU/mL developed 24 h postinfection, but the virus
was undetectable by day 4 (Figure 1). Similar viremia lev-
els, and no detectable disease occurred in 3 spiny rats
infected by the bite of an infectious mosquito (data not
shown). No correlation between peak viremia titer and age
could be established (n = 28, p = 0.08, R2 = 0.11, slope =
–0.1). Animals infected with the Venezuelan enzootic ID
strain 66637 exhibited a viremia level 1 log10PFU/mL
higher viremia, with a delayed mean peak of 4.8
log10PFU/mLon day 2 postinfection; this difference in titer
between virus strains was significant (p = 0.001).
Clearance of the virus occurred at the same time, by 4 days
postinfection (Figure 1). 
Virus titrations were performed on the spleen, heart,
brain, liver, and kidneys from 2 animals on each of days 1
to 4 postinfection. Only the spleen had detectable levels of
virus on days 1 (mean 2.6 log10PFU/mg) to 4 (mean 3.9
log10PFU/mg), with a peak on day 3 (4.1 log10PFU/mg)
(Figure 2). Peak virus titers in the spleen were reached 2
days later than with peak viremia level, and viremia was
undetectable by day 4 when virus could still be isolated
from the spleen. This finding suggests that the spleen is a
major site of viral replication or clearance from the circu-
lation after replication elsewhere. None of the other organs
had detectable infectious virus during the peak viremia
phase. 
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Figure 1. Viremia in spiny rats after subcutaneous infection with 3
log10 PFU of the enzootic Venezuelan equine encephalitis virus
strains Co97-0054 and 66637. Vertical bars represent standard
errors of the means. **p = 0.001.Because no VEEV was detected in organs other than
the spleen, RNA extractions and reverse transcription–
PCR, a more sensitive assay, were performed. The detec-
tion limit of the PCR was estimated at 0.3–1.3 PFU when
virus stocks of known titer were used (29), while the detec-
tion limit of the plaque assay with the volumes available
was 1.6 log10 PFU/mL. Viral RNA was detected in all
organs tested, and sequencing of the PCR amplicons con-
firmed the presence of VEEV strain Co97-0054. However,
detection of viral RNA does not necessarily indicate the
presence of replicating virus in the organs because the ani-
mals were not perfused, and residual virus could have been
present in blood. 
Animals injected IC with the subtype ID strain had a
peak viremia level 48 h postinfection, with titers from 2.6
to 3.2 log10PFU/mL. Unlike SC infection, IC infection
resulted in viremia levels for only 24 to 48 h (Table). The
lack of detectable disease in these animals indicates that
VEEV is not neurovirulent for these reservoir hosts.
Antibody Development
Neutralizing antibodies developed in all animals by day
7 postinfection, with a mean titer of 1:160. One year
postinfection, antibody titers for surviving animals were
1:20–1:640. Detectable viremia did not develop in animals
rechallenged with VEEV 1 year postinfection, but the ani-
mals did exhibit an 8-fold increase in antibody titers. All
animals infected IC had detectable neutralizing antibodies
15 days postinfection (1:320–1:1,280). 
Histopathologic Analysis
Histopathologic analysis was performed on small num-
bers of SC-infected animals on days 1 to 4 and day 7
postinoculation. Overall, pathologic changes were mild.
All 4 animals examined at day 1 showed an acute lym-
phadenitis in the draining, left popliteal lymph node. This
lesion was characterized by infiltration of the subcapsular
sinus and cortical follicles with neutrophils, with minimal
necrosis (Figure 3Aand B). This lesion was not seen in the
contralateral popliteal lymph node or in inguinal lymph
nodes and disappeared by day 2. No splenic lesions attrib-
utable to VEEV were seen at any time. Astriking degree of
hemosiderosis of the red pulp, along with mineralization of
the capsule and trabeculae, occurred in many animals,
including uninfected controls, and appeared to be a nor-
mal, age-related phenomenon in this species. No brain or
meningeal inflammation was seen at any time. Lesions of
other organs were sporadic, including interstitial or
periductal chronic inflammation in the salivary glands
(Figure 3C) and multifocal chronic inflammation in the
pancreas. Inflammatory foci were rarely seen in the heart
on days 1, 4, and 7 but were not seen in controls. The kid-
ney and thymus showed no lesions. Pathologic changes of
the viscera appeared to peak on day 3, when 2 of 3 rats
killed showed salivary gland pathology, 2 showed lung
pathology, 1 showed pancreatic pathology (Figure 3D),
and 2 showed liver pathology. 
One spiny rat had hypothermia and weight loss 24 h
after infection and died on day 3 postinfection. Necropsy
showed extensive liver pathology, characterized by steato-
sis, and confluent coagulative necrosis with a mixed,
mononuclear cell–predominant inflammatory infiltrate.
This animal also showed pulmonary edema and striking
alveolar hemosiderosis. Another animal exhibited alveolar
edema and patchy acute inflammation in the lung 3 days
after infection, while a different animal in this group dis-
played periportal acute inflammation in the liver. These
RESEARCH
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Figure 2. Comparison of the viremia titer with virus titer in the
spleen in 2 spiny rats/time point after subcutaneous infection with
3 log10 PFU of enzootic Venezuelan equine encephalitis virus
strain Co97-0054. Vertical bars represent standard errors of the
means. *p = 0.04, **p = 0.0003.lesions were not seen in other animals. The lung
histopathologic pattern seen in 2 animals on day 3 postin-
fection suggests that it might be VEEV-related; however,
we cannot rule out other processes in these colony-reared
animals.
Discussion
Subcutaneously VEEV infection induced little or no
disease in P. chrysaeolus, the principal reservoir host in
central Colombia. No signs of disease were seen after
intracranial injection and at least 96% of animals showed
no clinical signs after SC infection. Viremia was of low
magnitude and short duration after SC inoculation, and
was almost completely lacking after IC infection.
Seroconversion occurred by day 7 and was persistent for at
least 1 year. Histopathologic changes suggestive of viral
cytopathic effects were visible in the draining lymph nodes
24 h postinfection and by day 3, mild pancreatic patholo-
gy was visible. The inability to detect infectious virus in
the brain indicated that VEEV in these rats is probably not
neuroinvasive; even after IC inoculation, detectable dis-
ease did not develop in any rat, indicating that VEEVis not
neurovirulent in these animals. The only organ tested that
showed evidence of viral production was the spleen;
although viral RNAwas detected in all other organs, blood
contamination could not be ruled out. 
In SC-infected spiny rats detectable levels of viremia
developed for 3 days. The difference in viremia level
between the 2 enzootic strains has been reported for anoth-
er VEEV reservoir host, the cotton rat, using 2 strains of
Everglades virus (30). Strain variation could explain the
higher viremia titers reported for Panamanian spiny rats
infected with Panamanian VEEV (20) as compared to our
results with Colombian strains and animals. Other factors
that could explain this difference include 1) the
Panamanian virus used previously had a higher passage
history than our strain Co97-0054 (3 suckling mice versus
1 baby hamster kidney cell) that could have led to adapta-
tion for rodent replication (31); and 2) different species of
Proechimys from a different locality were used in the pre-
vious studies. 
Although the viremia titers we measured in spiny rats
were lower than those generated in laboratory mice (3–4
log10 versus 6–7 log10PFU/mL), they are sufficient to
infect enzootic mosquito vectors that have been shown to
be highly susceptible to infection by enzootic strains of
VEEV (12,32,33). Furthermore, Culex (Melanoconion)
pedroi, Cx. (Mel.) spissipes, Cx. (Mel.) vomerifer, Cx.
(Mel.) crybda, and Psorophora albipes mosquitoes, some
of which are natural VEEV vectors (12), captured in the
Monte San Miguel forest became infected after feeding on
viremic spiny rats (Carrara AS and Ferro C, unpub. data). 
No virus was found in the feces (data not shown).
Although saliva was not sampled, a previous study report-
ed virus in throat swabs of both spiny rats and cotton rats
(20). The pathologic changes we observed in the salivary
glands, although nonspecific, suggest the possibility of
VEEV infection in this site. Other studies have shown that
VEEV is horizontally transmitted among rodents (23); in
spiny rats, this transmission might occur orally during
social contact and probably not through urinary and feces
contamination. Further experiment designed specifically to
address this issue are needed. 
Virus titers in the spleen suggest it is a principal site of
viral replication in spiny rats. The draining lymph node, as
suggested by the presence of viral antigen and the high
Venezuelan Equine Encephalitis Virus Infection of Rats
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Figure 3. Histologic staining (hematoxylin and
eosin) of spiny rat lymph nodes (A and B), sali-
vary glands (C), and pancreas (D) after subcu-
taneous inoculation of 3 log10 PFU of
Venezuelan equine encephalitis virus strain
Co97-0054. A) Popliteal draining lymph node
24 h postinfection, showing the presence of a
polymorphonuclear leukocyte infiltrate (arrows).
B) Contralateral popliteal lymph node 24 hr
postinfection from same animal. No proinfiltra-
tion was visible. C) Chronic inflammation of the
salivary gland (arrows) day 3 postinfection. D)
Asenea with focal necrosis (arrows) day 3
postinfection. (Magnification x40.) level of neutrophil infiltration 24 h postinfection but absent
after 48 h, may be a site of initial viral replication as in
mice (34). Viral RNA detected in other organs indicates
either a very small amount of replication (below the plaque
assay detection limit) or the presence of RNA in viremic
blood. The involvement of the pancreas as a target for
VEEV replication during the later stages of infection is
reminiscent of similar findings for TC-83 (attenuated
VEEV vaccine strain) infection of mice and hamsters (3).
In mice, VEEV also disseminates to the spleen after initial
replication in the draining lymph node (35). However, an
important difference is that enzootic VEEV appears to be
nonneuroinvasive and nonneurovirulent in spiny rats, in
contrast to its uniformly neuroinvasive and neurovirulent
phenotype in laboratory mice. 
Neutralizing antibodies were detected in spiny rat
serum from 7 days to 1 year after VEEV infection. These
antibodies apparently prevent reinfection by homologous
(subtype ID) or heterologous (subtype IC, data not shown)
VEEV subtypes 1 year after infection. Therefore, spiny
rats appear unlikely to be susceptible to reinfection. Based
on human data after vaccination with the TC83 strain, neu-
tralizing antibodies are even longer lasting (36). 
Seroconversion of spiny rats in nature may present a
limiting factor to VEEV circulation, where the virus
depends on the constant generation of naive rodents. Their
long gestation and small litter sizes suggest that other
reservoir animals may be required to maintain enzootic
VEEV transmission when spiny rat populations are low
(10). Further studies are needed to investigate other possi-
ble reservoir hosts, such as bats and opossums, which have
also been shown to be seropositive in nature (12).
The high survival rates found in these rats after either
enzootic or epizootic VEEV infection (A.S. Carrara and C.
Ferro, unpub. data) support previous conclusions of their
role as reservoir hosts (37). By comparison, laboratory
mice (Mus musculus) exhibit a 100% mortality rate with
subtype ID strains of VEEV, including those we tested (6).
Horses have low mortality rates with enzootic strains, but
deaths from epizootic strains can exceed 50% (11). Human
mortality rates are generally <1% with both enzootic and
epizootic VEEV strains, but severe neurologic disease
develops in 4% to 14% of VEEV-infected patients <15
years of age; the mortality rate in these patients can reach
20% (38).
Not only did spiny rats survive VEEV infection (96%),
but they also showed little sign of illness or discomfort,
and their social behavior and fertility were not appreciably
altered by infection. No significant change in the fecundi-
ty of infected females was observed compared to uninfect-
ed colony animals (p = 0.86, Student t test). In contrast,
laboratory mice infected even with the attenuated VEEV
vaccine strain TC-83 exhibit aggressive behavior with
cage mates (39). The high survival rate of spiny rats in
spite of abundant replication suggests selection for resist-
ance to disease. The spiny rat is part of a very old (≈25 mil-
lion years) family (Echimyidae) (40), and long-term
exposure to VEEV may have selected for resistance to dis-
ease in these animals. 
Another possible explanation for the lack of disease in
spiny rats is that VEEV has been selected for attenuation
in these reservoir hosts. Other viruses, such as myxoma,
have been shown to adapt to their hosts through attenua-
tion. After its introduction into Australia for controlling the
imported European rabbit population, myxoma virus
underwent attenuation with concurrent selection for resist-
ance in the rabbit population (14).
Spiny rats may be a useful tool for studying VEE patho-
genesis and mechanisms of natural resistance. Additional
studies of the immunologic responses in these rodents, par-
ticularly innate immunity, may provide valuable informa-
tion that could be used to develop improved therapeutics
for human and equine VEE.
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